-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Mk+HsIbH0p/22WqBlquTAOiJtkPo4pmQE1CMFLaBdgiFykxPMcVvMbgO3n2DzvJk v6oJ427zUYBeS1YqgffoSA== 0000049071-03-000117.txt : 20031027 0000049071-03-000117.hdr.sgml : 20031027 20031027081843 ACCESSION NUMBER: 0000049071-03-000117 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20031027 ITEM INFORMATION: FILED AS OF DATE: 20031027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 03957480 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 8-K 1 er8koct.htm ITEM 12 HUMANA INC. 3RD QTR EARNINGS RELEASE er8koct


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report:   October 27, 2003
(Date of Earliest Event Reported)

 

 

 

HUMANA INC.
(Exact name of Registrant as specified in its Charter)

Delaware
(State of
Incorporation)

1-5975
(Commission
File Number)

61-0647538
(I.R.S. Employer
Tax Identification No.)

 

 

500 West Main Street
Louisville, KY 40202
(Address of principal executive offices, including zip code)

 

(502) 580-1000
(Registrant's telephone number, including area code)


 

Item 12

        
The following information is furnished pursuant to Item 12 - Disclosure of Results of Operations and Financial Condition.

        On October 27, 2003, Humana Inc. (the "Company" or
ARegistrant") issued a press release discussing third quarter results, a copy of which is attached hereto as Exhibit 99 and is incorporated herein by reference.

 

 

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.

BY:      /s/  Arthur P. Hipwell                         
        Arthur P. Hipwell
        Senior Vice President
        and General Counsel

 

Date:    October 27, 2003

 

INDEX TO EXHIBITS

Number                                         Description

    99                    Press Release, dated October 27, 2003, issued by the Company

EX-99 3 pr10-03.htm 3RD QTR EARNINGS RELEASE pr10-27-03

Humana Inc.
500 West Main Street
P.O. Box 1438
Louisville, KY 40201-1438
http:\www.humana.com

news release

For More Information Contact:

Regina Nethery
Humana Investor Relations
(502) 580-3644
E-mail: Rnethery@humana.com

Tom Noland
Humana Corporate Communications
(502) 580-3674
E-mail: Tnoland@humana.com

 

 

 

Humana Inc. Reports Financial Results for Third Quarter
and First Nine Months of 2003

 

 

     LOUISVILLE, KY (October 27, 2003) -- Humana Inc. (NYSE: HUM) today reported earnings per diluted share of $.38 for the third quarter ended September 30, 2003 ("3Q03") compared to $.31 in earnings per diluted share for the third quarter ended September 30, 2002 ("3Q02"), an increase of 23 percent.

     Net income of $62,119,000 for 3Q03 increased 19 percent over the prior year, up from $52,331,000 in 3Q02. Pretax margin of 3.0 percent for 3Q03 increased 30 basis points from the 3Q02 pretax margin of 2.7 percent.

     The increase in year-over-year results for 3Q03 was driven by the improvement in the company's Commercial segment.

     Results for the nine months ended September 30, 2003 ("the 2003 period") also improved over those for the nine months ended September 30, 2002 ("the 2002 period"). Earnings per diluted share for the 2003 period of $1.01 increased 17 percent compared to $.86 for the 2002 period. Net income of $162,625,000 increased 13 percent for the 2003 period versus $144,460,000 in the 2002 period. The company's pretax margin of 2.7 percent in the 2003 period increased 20 basis points over that for the 2002 period of 2.5 percent.

     Results for the 2003 period include the writedown of building and equipment of $17,233,000 pretax ($10,529,000 net of income tax benefit or $.07 per diluted share), gain on the sale of a venture capital investment of $15,200,000 pretax ($10,108,000 net of income taxes or $.06 per diluted share), and software abandonment charges of $13,527,000 pretax ($8,265,000 net of income tax benefit or $.05 per diluted share). Each of these items was recorded during the six months ended June 30, 2003. The net impact of these items reduced pretax income for the 2003 period by $15,560,000 ($8,686,000 net of income taxes or $.05 per diluted share).

     "We were pleased with the significant growth in profitability of our commercial segment in the third quarter, as well as our successful bid on the government side for the new TRICARE South region contract," said Michael B. McCallister, Humana's president and chief executive officer. "The government segment continues to provide a solid base of earnings as we expand our commercial segment's revenues, income and membership."

 

     Segment Results

     Commercial segment pretax income increased to $25,952,000 in 3Q03 from $4,540,000 in 3Q02. Commercial segment pretax margin of 1.5 percent in 3Q03 was 120 basis points higher than the related pretax margin of 0.3 percent in 3Q02. The improvement in year-over-year Commercial segment results during 3Q03 was driven by a 60 basis point decline in the medical expense ratio, coupled with gains in administrative efficiencies.

     For the 2003 period, Commercial segment pretax income increased to $106,948,000 versus $45,528,000 in the 2002 period. Pretax margin for the 2003 period in the Commercial segment was 2.1 percent, a 110 basis point increase from 1.0 percent in the 2002 period.

     Commercial segment pretax results for the 2003 period include software abandonment charges of $13,527,000, gain on the sale of a venture capital investment of $12,423,000 and the writedown of building and equipment of $4,325,000. Each of these items was recorded during the six months ended June 30, 2003.

     Government segment pretax income of $67,460,000 in 3Q03 compares to 3Q02 Government segment pretax income of $72,417,000. Pretax margin for the Government segment decreased 70 basis points to 4.8 percent in 3Q03 compared to 5.5 percent in 3Q02. The decline in year-over-year Government segment results during 3Q03 was primarily driven by an increase in the TRICARE medical expense ratio, partially offset by improvement in the medical expense ratio for the Medicare+Choice business.

     Government segment pretax income for the 2003 period decreased to $138,056,000 from $166,913,000 in the 2002 period. Government segment pretax margin was 3.4 percent during the 2003 period versus 4.2 percent in the 2002 period.

     Government segment pretax results for the 2003 period include the writedown of building and equipment of $12,908,000 and gain on the sale of a venture capital investment of $2,777,000. Each of these items was recorded during the six months ended June 30, 2003.

 

     Revenues and Membership

     Consolidated revenues for 3Q03 totaled $3,111,765,000, compared to $2,841,627,000 in 3Q02, a 10 percent increase. Medical membership as of September 30, 2003 totaled 6,625,100, essentially unchanged compared to the 6,631,400 medical members as of September 30, 2002.

     For the 2003 period, consolidated revenues were $9,073,439,000 versus $8,406,149,000 in the 2002 period, an increase of 8 percent. Consolidated revenues for the 2003 period include the gain on the sale of a venture capital investment of $15,200,000 recorded during the six months ended June 30, 2003.

     Commercial segment premiums and administrative services fees totaled $1,679,518,000 during 3Q03 compared to a total of $1,491,270,000 during 3Q02, or 13 percent higher than in the prior year. Commercial segment medical membership was 3,036,400 as of September 30, 2003, a growth of 2 percent from September 30, 2002. Per member premiums for the Commercial segment fully insured medical business, net of benefit changes, increased in the range of 12 to 14 percent during 3Q03 compared to 3Q02.

     Commercial segment premiums and administrative services fees for the 2003 period were $4,985,574,000 versus $4,405,068,000 in the 2002 period, an increase of 13 percent.

     Government segment premiums and administrative services fees for 3Q03 totaled $1,403,764,000, or 6 percent higher than the related 3Q02 premiums and administrative services fees of $1,322,122,000.

     Medicare+Choice membership totaled 324,600 at September 30, 2003, a decline of 24,400 members from the prior year's quarter. Per member premiums for the Medicare+Choice business, net of benefit changes, increased in the range of 4 to 6 percent during 3Q03 compared to 3Q02.

     TRICARE's insured membership totaled 1,746,300 at September 30, 2003, versus comparable membership at September 30, 2002 of 1,755,700. TRICARE ASO membership was 1,057,000 at September 30, 2003, up 2 percent from September 30, 2002 membership of 1,038,400. TRICARE premium revenues and administrative services fees increased year-over-year by approximately 18 percent during 3Q03 due to a change in the monthly base revenue effective in July 2003.

     Medicaid membership of 460,800 at September 30, 2003 declined by approximately 9 percent from September 30, 2002. Approximately 84 percent of the company's Medicaid membership is in Puerto Rico. Per member premiums for the Medicaid business, net of benefit changes, increased in the range of 8 to 10 percent during 3Q03 versus 3Q02.

     Government segment premiums and administrative services fees for the 2003 period were $3,986,866,000 versus $3,922,719,000 in the 2002 period, an increase of 2 percent.

 

     Medical and SG&A Expenses

     The company's 3Q03 medical expense ratio (medical expenses as a percent of premiums) of 83.8 percent increased 20 basis points compared to the 3Q02 medical expense ratio of 83.6 percent.

     For the 2003 period, the medical expense ratio was 83.7 percent, unchanged from that for the 2002 period.

     The selling, general and administrative ("SG&A") expense ratio (SG&A expenses as a percent of premiums plus administrative services fees) for 3Q03 of 14.9 percent decreased by 30 basis points from the 3Q02 SG&A ratio of 15.2 percent.

     For the 2003 period, the SG&A expense ratio was 15.3 percent compared to 15.4 percent in the 2002 period. SG&A expenses for the 2003 period include the writedown of building and equipment of $17,233,000 recorded during the six months ended June 30, 2003. This resulted in an increase to the 2003 period SG&A ratio of 20 basis points.

 

     Cash flows from operations

     Cash flows provided by operations for 3Q03 of $69,654,000 compared to cash flows provided by operations of $82,613,000 in 3Q02 due to normal fluctuation in working capital items. Neither quarter's cash flows from operations were impacted by the timing of the monthly receipt of the Medicare+Choice premium payment from the Centers for Medicare and Medicaid Services ("CMS").

     The fixed monthly Medicare+Choice premium payment from CMS is due to Humana on the first day of each month. However, if the first of the month falls on a weekend or a holiday, the company receives that payment on the last business day of the prior month, often resulting in a significant impact on cash flows from operations.

     Cash flows provided by operations for the 2003 period totaled $122,920,000, inclusive of the negative impact of $205,755,000 from the timing of the receipt of the premium payment from CMS. Cash flows used in operations for the 2002 period of $101,302,000 included the negative impact of $216,628,000 related to the timing of the premium payment receipt from CMS.

 

     Non-GAAP Financial Measures

     There were no non-GAAP financial measures for 3Q03 or 3Q02. The following is a reconciliation of the most directly comparable financial measures prepared in accordance with accounting principles generally accepted in the United States, or GAAP, to certain non-GAAP financial measures used by the company for the 2003 period and 2002 period.

 

 

For the nine months ended September 30,

 

 

2003

 

2002

 

 

(in thousands)

 

 

 

 

 

 

 

GAAP operating cash flows

 

$

  122,920

 

$

(101,302)

  Timing of premium payment
  receipt from CMS

 

 

  205,755

 

 


 216,628

Non-GAAP operating cash flows1

 

$

  328,675

 

$

 115,326

     1 Management believes the difference in timing of this cash event between periods may be so significant as to distort a particular period's trend in operating cash flows. Management believes that meaningful analysis of our financial performance requires an understanding of the factors underlying that performance and our judgments about the relevance of a factor to normal operating results. In some cases, large factors or events may obscure short-term patterns and long-term trends. When reviewing and analyzing our cash flow position, management apportions the appropriate CMS premium payment in each month. To do otherwise would distort a meaningful analysis of our cash flow. Decisions such as management's forecast or business plans regarding cash flow, therefore, use this non-GAAP financial measure.

 

     Share Repurchase Program

     In July 2003, the company announced that its Board of Directors authorized the use of up to $100 million for the repurchase of its common shares, exclusive of shares repurchased in connection with employee stock plans. During 3Q03, there were no shares repurchased under the July 2003 authorization. However, during 3Q03 the company repurchased 1,412,000 shares for an aggregate purchase price of $23,127,000, an average price of $16.38 per share in connection with employee stock plans.

 

     Guidance

     The company offers the GAAP guidance detailed below for the investor community.

     For the Fourth Quarter Ending December 31, 2003

  • Earnings per diluted share of $.39 to $.41.

     For the Year Ending December 31, 2003

  • Earnings per diluted share of $1.40 to $1.42 (includes $.05 net loss per diluted share related to the gain on the sale of a venture capital investment, writedown of building and equipment, and software abandonment charges).
  • Consolidated revenues of over $12 billion.
  • Commercial segment pretax income of over $125 million (includes net expense of $5.4 million related to software abandonment charges, gain on the sale of a venture capital investment and writedown of building and equipment).
  • Growth in Commercial segment medical membership of 2 to 3 percent for fully insured and ASO products combined.
  • Growth in per member premiums, net of benefit changes, in the range of 12 to 14 percent for Commercial segment fully insured medical business.
  • Increases in per member Commercial segment fully insured medical costs in the range of 12 to 14 percent.
  • Commercial segment SG&A ratio of between 16.5 and 16.9 percent (includes the impact of the write-down of building and equipment of $4.3 million).
  • Medicare+Choice membership of between 325,000 and 330,000 by year end.
  • Growth in per member premiums, net of benefit changes, in the range of 4 to 6 percent for Medicare+Choice business.
  • Increases in per member Medicare+Choice medical costs in the range of 4 to 6 percent.
  • Pretax margin for the company's TRICARE business of approximately 3 percent.
  • Government segment SG&A ratio of between 12.8 and 13.2 percent (includes impact of the write-down of building and equipment of $12.9 million).
  • Cash flows provided by operations of between $400 million and $425 million.
  • Capital expenditures of approximately $95 million.
  • An effective tax rate of approximately 34 percent.

     For the Year Ending December 31, 2004

  • Earnings per diluted share of approximately $1.60 (range of $1.55 to $1.65).
  • Consolidated revenues of over $13 billion.
  • Commercial segment pretax income of over $170 million.
  • Growth in Commercial segment medical membership of 6 to 9 percent for fully insured and ASO products combined, with growth of over 200 thousand members in the first quarter. (Approximately 60 to 70 percent of the 2004 growth is anticipated to be in ASO products.)
  • Growth in per member premiums, net of benefit changes, in the range of 11 to 13 percent for Commercial segment fully insured medical business.
  • Increases in per member Commercial segment fully insured medical costs in the range of 11 to 13 percent.
  • Commercial segment SG&A ratio of between 15.8 and 16.2 percent.
  • Medicare+Choice membership of between 325,000 and 350,000 by year end.
  • Growth in per member premiums, net of benefit changes, in the range of 2 to 4 percent for Medicare+Choice business.
  • Increases in per member Medicare+Choice medical costs in the range of 2 to 4 percent.
  • Pretax margin for the company's TRICARE business in the range of 2 to 4 percent.
  • Government segment SG&A ratio of between 12.8 and 13.2 percent.
  • An effective tax rate of approximately 34 percent.

 

     Conference Call

     Humana will host a conference call, as well as a virtual slide presentation, at 9:00 a.m. eastern time today to discuss its financial results for the quarter and earnings guidance.

     All parties interested in the audio only portion of the conference call are invited to dial 888-625-7430. No password is required. The company suggests participants dial in approximately ten minutes in advance of the call.

     A live virtual presentation (audio with slides) will be available and may be accessed via Humana's Investor Relations page at www.humana.com. The company suggests web participants sign on approximately 15 minutes in advance of the call. The company also suggests web participants visit the site well in advance of the call to run a system test and to download any free software needed to view the presentation.

     For those unable to participate in the live event, the virtual presentation archive will be available in the Presentations section of the Investor Relations page at www.humana.com, approximately two hours following the live web cast. An audio recording of the conference call will also be available in the Audio Archives located on the Investor Relations page at www.humana.com approximately two hours after the live call.

***********

     This news release contains forward-looking statements. The forward-looking statements made in the news release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be significantly impacted by certain risks and uncertainties described in the following documents, as filed by Humana with the Securities and Exchange Commission:

  • Form 10-K for the year ended December 31, 2002;
  • Form 10-Qs for the quarters ended March 31, 2003 and June 30, 2003.

***********

     Humana Inc., headquartered in Louisville, Kentucky, is one of the nation's largest publicly traded health benefits companies, with approximately 6.6 million medical members located primarily in 18 states and Puerto Rico. Humana offers coordinated health insurance coverage and related services -- through traditional and Internet-based plans -- to employer groups, government-sponsored plans, and individuals.

     More information regarding Humana is available via the Internet at www.humana.com, including copies of:

  • Annual report to stockholders;
  • Securities and Exchange Commission filings;
  • Most recent investor conference presentation;
  • Quarterly earnings press releases;
  • Audio archive of most recent earnings release conference call;
  • Calendar of events (includes upcoming earnings conference call dates, times, and access number, as well as planned participation in investor conferences).

Humana Inc.

In thousands

September 30,

Percent

Ending Medical Membership

2003

2002

Difference

Change

Commercial:

Fully insured

2,324.6

2,323.6

1.0

0.0

ASO

711.8

658.6

53.2

8.1

Total Commercial

3,036.4

2,982.2

54.2

1.8

Government:

Medicare+Choice

324.6

349.0

(24.4)

(7.0)

Medicaid

460.8

506.1

(45.3)

(9.0)

TRICARE

1,746.3

1,755.7

(9.4)

(0.5)

TRICARE ASO

1,057.0

1,038.4

18.6

1.8

Total Government

3,588.7

3,649.2

(60.5)

(1.7)

Total ending medical membership

6,625.1

6,631.4

(6.3)

(0.1)

September 30,

Percent

Ending Specialty Membership

2003

2002

Difference

Change

Commercial:

Dental-fully insured

753.0

777.5

(24.5)

(3.2)

Dental-ASO

362.7

306.8

55.9

18.2

Total Dental

1,115.7

1,084.3

31.4

2.9

Group life

504.4

522.1

(17.7)

(3.4)

Short-term disability

19.0

23.0

(4.0)

(17.4)

Total ending specialty membership

1,639.1

1,629.4

9.7

0.6

Three months ended

Nine months ended

September 30,

September 30,

Premiums

2003

2002

2003

2002

Commercial:

Fully insured medical

$1,567,284

$1,379,897

$4,655,856

$4,076,431

Specialty

81,199

84,806

238,737

251,347

Total Commercial

1,648,483

1,464,703

4,894,593

4,327,778

Government:

Medicare+Choice

626,840

647,265

1,893,114

1,981,931

Medicaid

120,498

118,902

357,733

343,389

TRICARE

620,477

521,466

1,627,212

1,484,789

Total Government

1,367,815

1,287,633

3,878,059

3,810,109

Total premiums

$3,016,298

$2,752,336

$8,772,652

$8,137,887

Three months ended

Nine months ended

September 30,

September 30,

Administrative services fees

2003

2002

2003

2002

Commercial

$31,035

$26,567

$90,981

$77,290

Government

35,949

34,489

108,807

112,610

Total Administrative services fees

$66,984

$61,056

$199,788

$189,900

Humana Inc.

Dollars in thousands, except per share results

Three months ended

Nine months ended

September 30,

September 30,

Consolidated Statements of Income

2003

2002

2003

2002

Revenues:

Premiums

$3,016,298

$2,752,336

$8,772,652

$8,137,887

Administrative services fees

66,984

61,056

199,788

189,900

Investment income

26,219

25,706

95,264

(a)

72,695

Other income

2,264

2,529

5,735

5,667

Total revenues

3,111,765

2,841,627

9,073,439

8,406,149

Operating expenses:

Medical

2,528,123

2,301,021

7,344,534

6,811,748

Selling, general and administrative

458,381

429,019

1,371,196

(b)

1,278,516

Depreciation

24,723

26,592

91,009

(c)

78,763

Other intangible amortization

2,389

3,931

9,223

11,793

Total operating expenses

3,013,616

2,760,563

8,815,962

8,180,820

Income from operations

98,149

81,064

257,477

225,329

Interest expense

4,737

4,107

12,473

12,888

Income before income taxes

93,412

76,957

245,004

(d)

212,441

Provision for income taxes

31,293

24,626

82,379

67,981

Net income

$62,119

$52,331

$162,625

(d)

$144,460

Basic earnings per common share

$0.39

$0.32

$1.03

$0.88

Diluted earnings per common share

$0.38

$0.31

$1.01

(d)

$0.86

Shares used in computing basic earnings per common share (000's)

159,454

163,933

158,202

164,348

Shares used in computing diluted earnings per common share (000's)

162,549

167,534

161,384

168,242

Operating Results by Segment

Commercial pretax income

25,952

4,540

106,948

(d)

45,528

Government pretax income

67,460

72,417

138,056

(d)

166,913

Consolidated pretax income

93,412

76,957

245,004

(d)

212,441

Key Ratios

Medical expense ratio

Commercial

83.7%

84.3%

82.7%

83.4%

Government

84.0%

82.8%

85.0%

84.1%

Total

83.8%

83.6%

83.7%

83.7%

Selling, general, and administrative expense ratio

Commercial

16.6%

17.0%

16.8%

(e)

17.0%

Government

12.9%

13.3%

13.4%

(e)

13.5%

Total

14.9%

15.2%

15.3%

(e)

15.4%

(a) Includes a gain on the sale of a venture capital investment of $15.2 million pretax ($10.1 million after tax, or $0.06 per diluted share).

(b) Includes a writedown of building and equipment of $17.2 million pretax ($10.5 million after tax, or $0.07 per diluted share).

(c) Includes accelerated depreciation of abandoned software $13.5 million pretax ($8.3 million after tax, or $0.05 per diluted share).

(d) Includes the total impact of items (a), (b), and (c) of $15.5 million pretax ($8.7 million after tax, or $0.05 per diluted share). Of the

$15.5 million pretax, $5.4 million relates to Commercial and $10.1 million relates to Government.

(e) Includes the impact of a writedown of building and equipment of $17.2 million pretax ($4.3 million for Commercial and $12.9 for

Government) which increased the selling, general, and administrative expense ratio by 20 basis points (10 basis points for Commercial

and 40 basis points for Government).

Humana Inc.

Dollars in thousands, except per share results

September 30,

June 30,

December 31,

Consolidated Balance Sheets

2003

2003

2002

Assets

Current assets:

Cash and cash equivalents

$635,837

$754,942

$721,357

Investment securities

1,682,402

1,399,220

1,405,833

Receivables, net:

Premiums

461,684

402,821

348,562

Administrative services fees

10,952

36,688

68,316

Other

288,836

223,800

250,857

Total current assets

3,079,711

2,817,471

2,794,925

Property and equipment, net

413,402

417,446

459,842

Other assets:

Long-term investment securities

320,464

329,178

288,724

Goodwill

776,874

776,874

776,874

Other

159,273

152,885

279,665

Total other assets

1,256,611

1,258,937

1,345,263

Total assets

$4,749,724

$4,493,854

$4,600,030

Liabilities and Stockholders' Equity

Current liabilities:

Medical and other expenses payable

$1,296,566

$1,287,364

$1,142,131

Trade accounts payable and accrued expenses

438,926

455,541

552,689

Book overdraft

218,751

79,536

94,882

Unearned premium revenues

108,161

100,445

335,757

Short-term debt

-

265,000

265,000

Total current liabilities

2,062,404

2,187,886

2,390,459

Long-term debt

644,440

334,610

339,913

Other long-term liabilities

283,756

265,098

263,184

Total liabilities

2,990,600

2,787,594

2,993,556

Commitments and contingencies

Stockholders' equity:

Preferred stock, $1 par; 10,000,000 shares authorized; none issued

-

-

-

Common stock, $0.16 2/3 par; 300,000,000 shares authorized;

173,112,860 shares issued at September 30, 2003

28,854

28,708

28,556

Capital in excess of par value

961,015

938,648

931,089

Retained earnings

883,502

821,383

720,877

Accumulated other comprehensive income

20,086

29,839

22,455

Unearned restricted stock compensation

(357)

(1,469)

(6,516)

Treasury stock, at cost, 12,018,281 shares at September 30, 2003

(133,976)

(110,849)

(89,987)

Total stockholders' equity

1,759,124

1,706,260

1,606,474

Total liabilities and stockholders' equity

$4,749,724

$4,493,854

$4,600,030

Debt to total capitalization ratio

26.8%

26.0%

27.4%

Humana Inc.

Dollars in thousands

Three months ended

Nine months ended

September 30,

September 30,

Consolidated Statements of Cash Flows

2003

2002

2003

2002

Cash flows from operating activities

Net income

$62,119

$52,331

$162,625

$144,460

Adjustments to reconcile net income to net

Cash provided by operating activities:

Building and equipment writedown

-

-

17,233

-

Depreciation and amortization

27,112

30,523

86,705

90,556

Accelerated depreciation of software

-

-

13,527

-

Provision for deferred income taxes

19,159

11,183

30,213

34,221

Changes in operating assets and liabilities:

Receivables

(33,127)

(39,819)

7,509

(231,012)

Other assets

5,605

27,996

(17,022)

268

Medical and other expenses payable

9,202

(30,258)

154,435

78,045

Other liabilities

(25,830)

21,424

(85,899)

4,742

Unearned revenues

7,716

7,015

(227,596)

(235,063)

Other

(2,302)

2,218

(18,810)

12,481

Net cash provided by (used in) operating activities

69,654

82,613

122,920

(a)

(101,302)

(b)

Cash flows from investing activities

Purchases of property and equipment, net

(20,020)

(26,851)

(62,497)

(83,581)

Divestiture

-

-

-

1,109

Purchases of investment securities

(1,398,118)

(641,706)

(3,659,394)

(1,639,803)

Proceeds from maturities of investment securities

200,535

95,228

585,461

273,199

Proceeds from sales of investment securities

871,272

469,688

2,768,446

1,339,124

Net cash used in investing activities

(346,331)

(103,641)

(367,984)

(109,952)

Cash flows from financing activities

Proceeds from swap exchange

-

-

31,556

-

Proceeds from issuance of senior notes

299,139

-

299,139

-

Net commercial paper conduit (repayments) borrowings

(265,000)

-

(265,000)

2,000

Change in book overdraft

139,215

(28,877)

123,869

(48,355)

Common stock repurchases

(23,127)

(25,439)

(44,147)

(25,439)

Other

7,345

380

14,127

7,364

Net cash provided by (used in) provided by financing activities

157,572

(53,936)

159,544

(64,430)

Decrease in cash and cash equivalents

(119,105)

(74,964)

(85,520)

(275,684)

Cash and cash equivalents at beginning of period

754,942

450,700

721,357

651,420

Cash and cash equivalents at end of period

$635,837

$375,736

$635,837

$375,736

(a) Includes the negative impact of receiving the $205.8 million January 2003 CMS payment early in December 2002. This receipt is payable

to us on the first day of the month. When the first day of the month falls on a weekend or holiday (e.g. New Year's Day), we receive this

payment at the end of the previous month.

(b) Includes the negative impact of receiving the $216.6 million January 2002 CMS payment early in December 2001. This receipt is payable

to us on the first day of the month. When the first day of the month falls on a weekend or holiday (e.g. New Year's Day), we receive this

payment at the end of the previous month.

 

Humana Inc.

Percentage of Ending Membership Under Capitation Arrangements

Commercial Segment

Government Segment

Consol.

Fully

Total

Medicare

TRICARE

Total

Total

Insured

ASO

Segment

+Choice

Medicaid

TRICARE

ASO

Segment

Medical

September 30, 2003

Capitated HMO

   Hospital system based A

5.6%

-

4.3%

12.2%

2.9%

-

-

1.5%

2.8%

Capitated HMO

   Physician group based A

3.3%

-

2.5%

1.8%

47.2%

-

-

6.2%

4.5%

Risk-sharing B

2.7%

-

2.1%

48.7%

44.0%

-

-

10.0%

6.4%

All other membership

88.4%

100.0%

91.1%

37.3%

5.9%

100.0%

100.0%

82.3%

86.3%

   Total

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

September 30, 2002

Capitated HMO

   Hospital system based A

6.3%

-

4.9%

13.5%

2.2%

-

-

1.6%

3.1%

Capitated HMO

   Physician group based A

3.2%

-

2.5%

3.3%

47.5%

-

-

6.9%

4.9%

Risk-sharing B

3.0%

-

2.3%

42.8%

42.9%

-

-

10.0%

6.6%

All other membership

87.5%

100.0%

90.3%

40.4%

7.4%

100.0%

100.0%

81.5%

85.4%

   Total

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

100.0%

A - In a limited number of circumstances, we contract with hospitals and physicians to accept financial risk for a defined

set of HMO membership. In transferring this risk, we prepay these providers a monthly fixed-fee per member to

coordinate substantially all of the medical care for their capitated HMO membership, including some health benefit

administrative functions and claims processing. For these capitated HMO arrangements, we generally agree to

reimbursement rates that target a medical expense ratio ranging from 82% to 89%. Providers participating in hospital-

based capitated HMO arrangements generally receive a monthly payment for all of the services within their system for

their HMO membership. Providers participating in physician-based capitated HMO arrangements generally have

subcontracted specialist physicians and are responsible for reimbursing such hospitals and physicians for services

rendered to their HMO membership.

B - In some circumstances, we contract with physicians under risk-sharing arrangements whereby physicians have

assumed some level of risk for all or a portion of the medical costs of their HMO membership. Although these

arrangements do include capitation payments for services rendered, we process substantially all of the claims under

these arrangements.

 

Humana Inc.

Medical Claim Reserves - Details and Statistics

Change in medical and other expenses payable:

The change in medical and other expenses payable is summarized as follows:

For the Nine

For the Twelve

Months Ended

Months Ended

September 30, 2003

December 31, 2002

Balances at January 1

$1,142,131

$1,086,386

Incurred related to:

     Current year

7,420,343

9,125,915

     Prior years - TRICARE

(33,852)

25,685

(1)

     Prior years - non-TRICARE

(41,957)

(2)

(13,404)

(2)

Total incurred

7,344,534

9,138,196

Paid related to:

     Current year

(6,162,062)

(8,002,610)

     Prior years

(1,028,037)

(1,079,841)

Total paid

(7,190,099)

(9,082,451)

Balances at end of period

$1,296,566

$1,142,131

(1)   Changes in estimates of medical expenses payable for TRICARE may result from issues that entitle us

        to additional revenues derived from change orders or the bid price adjustment process, which was the

        case with substantially all of the unfavorable development for prior periods recognized during 2002.

(2)   Changes in estimates of non-TRICARE incurred claims for prior years recognized during 2003 and 2002

        related primarily to our commercial lines of business. The impact of any reduction of "incurred related

        to prior years" claims may be offset as we re-establish the "incurred related to current year". Our

        reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for

        our claims within a level of confidence required to meet actuarial standards. Thus, only when the

        release of a prior year reserve is not offset with the same level of conservatism in estimating the current

        year reserve will the redundancy reduce medical expense. We have consistently applied this

        methodology in determining our best estimate for unpaid claims liability in each period.

 

Humana Inc.

Dollars in thousands

Medical Claim Reserves - Details and Statistics

Medical and Other Expenses Payable Detail:

September 30,

June 30,

December 31,

2003

2003

2002

A   IBNR and other medical expenses payable

$788,124

$778,460

$650,606

B   TRICARE IBNR

280,429

232,591

212,826

C   TRICARE other medical expenses payable

25,941

24,677

37,793

D   Unprocessed claim inventories

106,800

92,100

92,300

E   Processed claim inventories

47,515

126,516

105,422

F   Payable to pharmacy benefit administrator

47,757

33,020

43,184

      Total medical and other expenses payable

$1,296,566

$1,287,364

$1,142,131

A   IBNR represents an estimate of medical expenses payable for claims incurred but not reported (IBNR) at the balance

      sheet date. The level of IBNR is primarily impacted by membership levels, medical claim trends and the receipt cycle

      time, which represents the length of time between when a claim is initially incurred and when the claim form is

      received (i.e. a shorter time span results in lower reserves for claims IBNR).

B   TRICARE IBNR has increased primarily due to an increase in claim inventories at our third party claim administrator

      for claims not submitted electronically.

C   TRICARE other medical expense payable may include liabilities to subcontractors and/or risk share payables to the

      Department of Defense. The level of these balances may fluctuate from period to period due to the timing of payment

      (cutoff) and whether or not the balances are payables or receivables (receivables from the Department of Defense

      are classified as "receivables" in our balance sheet).

D   Unprocessed claim inventories represent the estimated valuation of claims received but not yet fully processed.

      TRICARE claim inventories are not included in this amount as an independent third party administrator processes

      all TRICARE medical claims on our behalf. Reserves for TRICARE claims inventory are included in TRICARE IBNR.

E   Processed claim inventories represent the estimated valuation of processed claims that are in the post claim

      adjudication process, which consists of administrative functions such as audit and check batching and handling.

F   The balance due to our pharmacy benefit administrator fluctuates due to bi-weekly payments and the month-end

      cutoff.

Receipt Cycle Time:

Due to increasing electronic connectivity and other efficiencies gained by our providers with regards to the claim

submission process, the average length of time between when a claim was initially incurred and when the claim form

was received has generally shortened over the past several years. Below is a summary:

Average # of Days from Incurred Date to Receipt Date (1)

2003

2002

Change

% Change

1st Quarter Average

17.1

19.0

(1.9)

-10.0%

2nd Quarter Average

16.7

18.1

(1.4)

-7.7%

3rd Quarter Average

16.6

17.3

(0.7)

-4.0%

4th Quarter Average

0.0

16.9

n/a

n/a

Full Year Average

16.8

17.8

(1.0)

-5.6%

(1)   Receipt cycle time data for our 2 largest claim processing platforms representing approximately 90% of our

       Claims volume.

 

 

Humana Inc.

Medical Claim Reserves - Details and Statistics

Unprocessed Claim Inventories:

The estimated valuation and number of claims on hand that are yet to be processed are as follows:

Estimated

Number

Valuation

Claim Item

of Days

Date

(000)

Counts

On Hand

12/31/2001

$125,400

518,100

5.0

3/31/2002

$121,000

559,600

5.2

6/30/2002

$110,300

513,100

4.8

9/30/2002

$108,800

496,200

4.8

12/31/2002

$92,300

424,200

4.5

3/31/2003

$99,000

421,700

4.4

6/30/2003

$92,100

446,600

4.7

9/30/2003

$106,800

528,400

5.8

Days in Claims Payable (Quarterly):

A common metric for monitoring medical claim reserve levels relative to the medical claim expenses is days in claims

payable, or DCP, which represents the medical claim liabilities at the end of the period divided by average medical

expenses per day in the quarterly period. Since we have some providers under capitation payment arrangements (which

do not require a medical claim IBNR reserve), we have also summarized this metric excluding capitation expenses.

Days

DCP

in Claims

Annual

Excluding

Annual

Quarter Ended

Payable (DCP)

Change

% Change

Capitation

Change

% Change

12/31/2001

47.4

(3.9)

-7.6%

57.1

(4.4)

-7.2%

3/31/2002

47.2

(2.3)

-4.6%

56.2

(3.4)

-5.7%

6/30/2002

46.8

(3.1)

-6.2%

55.3

(4.7)

-7.8%

9/30/2002

46.6

(2.5)

-5.1%

55.3

(3.9)

-6.6%

12/31/2002

45.2

(2.2)

-4.6%

53.3

(3.8)

-6.7%

3/31/2003

46.5

(0.7)

-1.5%

54.7

(1.5)

-2.7%

6/30/2003

47.9

1.1

2.4%

56.2

0.9

1.6%

9/30/2003

47.2

0.6

1.3%

54.5

(0.8)

-1.4%

This metric fluctuates due to all of the issues reviewed above, including the change in the receipt cycle time, the change

in medical claim inventories, the change in TRICARE liability balances, and the timing of our bi-weekly payment

to our pharmacy benefits administrator. An annual recap follows:

2003

2002

4th quarter-prior year

45.2

47.4

       Impact of change in claim receipt cycle time

(0.5)

(2.6)

       Impact of change in unprocessed claim inventories

0.5

(1.3)

       Impact of change in processed claim inventories

(2.2)

0.2

       Impact of changing TRICARE reserve balances

2.5

0.3

       Impact of change in pharmacy payment cutoff

0.2

0.7

       All other

1.5

0.5

    Year to date-current year

47.2

45.2

-----END PRIVACY-ENHANCED MESSAGE-----